MatthewCaseyRiddleJr.MD
Endocrinology • Portland, ORDiabetes, Lipid Metabolism
Professor of Medicine, Oregon Health & Sci University
Are you Dr. Riddle?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 41 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
3181 SW Sam Jackson Park Rd
Portland, OR 97239Phone+1 503-494-5732Fax+1 503-494-5883
Summary
- Dr. Matthew Riddle Jr., MD is an endocrinologist in Portland, Oregon. He is currently licensed to practice medicine in Oregon and Illinois. He is affiliated with OHSU Hospital and is a Professor of Medicine at Oregon Health & Sci University.
Education & Training
Rush University Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 1969 - 1971- Rush University Medical CenterResidency, Internal Medicine, 1968 - 1969
- Rush University Medical CenterInternship, Internal Medicine, 1964 - 1965
Harvard Medical SchoolClass of 1964
Certifications & Licensure
IL State Medical License 1966 - Present
OR State Medical License 1967 - 2023
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
- Fellow (FACE) American Association of Clinical Endocrinology
Clinical Trials
- How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics Start of enrollment: 2007 Mar 01
Publications & Presentations
PubMed
- 583 citationsSotagliflozin in Patients with Diabetes and Chronic Kidney Disease.Deepak L. Bhatt, Michael Szarek, Bertram Pitt, Christopher P. Cannon, Lawrence A. Leiter
The New England Journal of Medicine. 2021-01-14 - 966 citationsSotagliflozin in Patients with Diabetes and Recent Worsening Heart FailureDeepak L. Bhatt, Michael Szarek, P. Gabriel Steg, Christopher P. Cannon, Lawrence A. Leiter
The New England Journal of Medicine. 2021-01-14 - 1006 citationsAlbiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled t...Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed, Ralph B. D'Agostino, Christopher B. Granger
Lancet. 2018-10-27
Press Mentions
Type 2 Diabetes Remission: New Guidelines Outline the Steps to Follow with a DoctorSeptember 7th, 2021- Type 2 Diabetes ‘Remission’ Is a Reality, Say Major OrganizationsSeptember 1st, 2021
Dulaglutide Reduces Cardiovascular Disease in People with Type 2 DiabetesJune 9th, 2019- Join now to see all
